Two studies investigated the effect of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes. In study 1, 27 outpatients with hypercholesterolaemia (16 statin-naïve, 11 switched from another statin) took atorvastatin (10 mg once daily) for 3 months. After 3 months, low-density lipoprotein cholesterol (LDL-C) had decreased significantly in both groups, high-density lipoprotein cholesterol (HDL-C) and estimated glomerular filtration rate had increased only in the statin-naïve group, and glycosylated haemoglobin (HbA 1c ) had not changed significantly in either group.
Introduction
Patients with type 2 diabetes mellitus have an increased risk of mortality due to both coronary heart disease and stroke. 1 − 5 Several large clinical trials have established that treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) prevents cardiovascular events in patients with diabetes. 6 − 10 The cardiovascular protective effect of statins is largely due to their low-density lipoprotein cholesterol (LDL-C)-lowering effect. 11 In addition, statins have been shown to possess potential pleiotropic effects, one of which is a renalprotective effect, although the precise mechanism is unknown. 12 − 16 Statins may, however, worsen blood glucose control in patients with diabetes and whether statins can be used safely in diabetic patients is a cause for concern. Several large randomized clinical trials have shown conflicting results concerning the risk of diabetes in patients taking statins. 17 − 22 Two studies were, therefore, undertaken to investigate the efficacy and safety of atorvastatin on glycaemic control and renal function in patients with type 2 diabetes mellitus.
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Department of Endocrinology of Tenri Hospital, Nara, Japan and were enrolled sequentially between July 2008 and April 2009.
Study 1 was a prospective study that included outpatients with type 2 diabetes who had hypercholesterolaemia (LDL-C concentration ≥ 120 mg/dl). The patients had either never previously taken statins or were previously being prescribed a statin other than atorvastatin. Patients were excluded from study 1 if they had abnormal asparate aminotransferase (AST) or alanine aminotransferase (ALT) elevation (over three times the upper limit of normal), or serum creatinine > 2.0 mg/dl. Study 2 was a retrospective study that included outpatients with type 2 diabetes with hypercholesterolaemia who had been maintained on atorvastatin for at least 4 years. At baseline patients had already taken atorvastatin for at least 1 year. Patients were excluded from study 2 if they had abnormal AST/ALT elevation (over three times the upper limit of normal), or serum creatinine > 2.0 mg/dl. Before participation in study 1, the details of the study were explained and written informed consent was obtained from all patients. For study 2, the data described in this paper were gathered retrospectively from patients' records, but inclusion was conditional on the subjects reading and signing an informed consent form. Both studies were approved by the Ethics Committee of Tenri Hospital.
STUDY DESIGN AND ASSESSMENTS

Study 1
Outpatients with type 2 diabetes who had hypercholesterolaemia were prescribed 10 mg atorvastatin to be taken once daily either after breakfast or after dinner. Patients' lipid profiles (total cholesterol, LDL-C, high-density lipoprotein cholesterol [HDL-C], triglycerides), glycosylated haemoglobin (HbA 1c ) and estimated glomerular filtration rate (eGFR) were compared before and after 3 months of treatment with atorvastatin. Total cholesterol, LDL-C, HDL-C, triglyceride and HbA 1c were assessed using standard laboratory tests. eGFR was calculated as follows: eGFR (ml/min per 1.73 m 2 ) = 0.741 × 175 × age -0.203 × creatinine -1.154 (male), or 0.742 × 175 × age -0.203 × creatinine -1.154 (female).
Drug safety was monitored by measuring hepatic function (AST, ALT, γ-glutamyl transferase [γGTP]), creatinine kinase, uric acid, creatinine and systolic and diastolic blood pressure, before and after 3 months of atorvastatin administration.
Study 2
For outpatients with type 2 diabetes with hypercholesterolaemia, who had been maintained on atorvastatin for at least 4 years, changes in total cholesterol, LDL-C, triglycerides, HbA 1c , and serum creatinine were extracted from the patients' clinical records and examined for the previous 3 years at intervals of 12 months.
STATISTICAL ANALYSES
The mean ± SD of the data were calculated and statistical analyses were performed using the JMP ® statistical software package, version 6 (SAS Japan Institute, Tokyo, Japan) for Windows ® . Statistical significances were tested using Wilcoxon's rank sum test, with statistical significance defined as P < 0.05 (two-tailed test).
Results
STUDY 1
Characteristics of the 27 patients with type 2 diabetes are shown in Table 1 . The mean ± SD age of these patients was 62.4 ± 9.8 years.
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Sixteen of the patients were statin-naïve (atorvastatin was administered as the first statin to these patients) and the remaining 11 patients were changed to atorvastatin.
Serum LDL-C decreased significantly after administration of avorvastatin for 3 months in both groups of patients (P < 0.01; Fig. 1A ). In contrast, HDL-C increased in both groups, although only the increase in the statinnaïve group was statistically significant (P < 0.05; Fig. 1B ). Mean ± SD triglycerides levels decreased from 203.8 ± 82.0 to 159.4 ± 74.9 mg/dl in the statin-naïve group and from 173.8 ± 111.4 to 119.5 ± 53.8 mg/dl in the substitution group, however neither of these decreases were statistically significant.
Serum HbA 1c levels showed little change over the 3-month period in either group (Fig.  2 ). There was a statistically significant increase in eGFR in the statin-naïve group (P < 0.05) but not in the group switched to atorvastatin from another statin ( Fig. 3 ). As shown in Table 2 , there were no significant differences in hepatic function, creatinine kinase, uric acid, creatinine, and systolic and diastolic blood pressure after 3 months' administration of atorvastatin.
No adverse events were reported and all patients were able to continue oral atorvastatin treatment.
STUDY 2
This retrospective study included 87 outpatients with type 2 diabetes (45 males and 42 females) with hypercholesterolaemia who had already taken atorvastatin for at least 4 years. The mean ± SD age of these patients was 63.1 ± 10.8 years. Over the 4-year period, the data showed a significant increase from baseline in HDL-C at 2 and 3 years (P < 0.01), a significant decrease in HbA 1c at 1 year (P < 0.05), 2 years (P < 0.01) and 3 years M Tanaka Atorvastatin in type 2 diabetes (P < 0.01), and a significant decrease in serum creatinine at 1 year (P < 0.01) ( Table 3 ).
Discussion
In study 1, 10 mg atorvastatin once daily decreased LDL-C significantly without worsening clinical parameters. In the UK Prospective Diabetes Study, it was shown that the most important risk factor for coronary heart disease in patients with type 2 diabetes was LDL-C. 23 Thus, atorvastatin could be a promising drug to prevent cardiovascular FIGURE 3 : Estimated glomerular filtration rate (eGFR) in outpatients with type 2 diabetes and hypercholesterolaemia (study 1) before (baseline) and 3 months after administration of atorvastatin 10 mg once daily, either as the first statin they had taken (statin-naïve) or switched from another statin (study 1; mean ± SD; *P < 0.05 versus before atorvastatin treatment; Wilcoxon's signed-rank test) After 3 months * M Tanaka Atorvastatin in type 2 diabetes events in patients with type 2 diabetes. In meta-analysis studies, statin treatment was shown to be associated with a small but significant increase in the incidence of diabetes. 24, 25 Moreover, several studies have suggested the possibility that statins might raise HbA 1c levels, although this adverse effect was slight. 20, 26 27 Thus, the slightly increased risk of deterioration of glycaemic control is favorably balanced by the benefit from statins in suppressing cardiovascular events and strokes, as seen in the Collaborative Atorvastatin Diabetes Study, where 10 mg atorvastatin suppressed cardiovascular events in patients with type 2 diabetes mellitus. 10 In study 1, atorvastatin increased eGFR in statin-naïve patients. Additionally, in study 2, patients taking atorvastatin did not show a decrease in serum creatinine after 3 years. Considering that eGFR declines with age, it is possible that atorvastatin might prevent a decrease in eGFR. Impaired renal function has been shown to be a risk factor for cardiovascular disease, 28 − 32 and the degree of decrease in urinary protein and albumin is associated with prevention of cardiovascular events. 33 − 35 Statins may improve renal function and the renoprotective effect of atorvastatin might be stronger than that of other statins. 36 The sub-analyses of the Treating to New Targets study 13 and the Greek Atorvastatin and Coronary Heart Disease Evaluation study 14 both showed that atorvastatin treatment improved renal function significantly. Thus, atorvastatin has the potential to suppress macrovascular events through an improvement in renal function.
There were several limitations to the present studies. Study 1, although a prospective study, had low patient numbers and no control group. Study 2 was a retrospective study and it is difficult to compare the results to study 1 and other prospective studies.
In conclusion, atorvastatin lowered high LDL-C concentrations and did not worsen glycaemic control in patients with type 2 diabetes. Moreover, the studies indicated that atorvastatin might improve renal function in these patients. Thus, atorvastatin may contribute to the prevention of cardiovascular events in patients with type 2 diabetes not only by decreasing LDL-C but also by preserving renal function.
